Men and women with type 2 diabetes mellitus have a shorter life expectancy than those without diabetes,1 and deaths from heart disease and stroke are more frequent in diabetics than in nondiabetics.2 While mortality from heart disease is declining in the general US population, the same is not true among diabetic subjects.3 The editorial by Fagan et al4 that addressed these greater cardiovascular risks and the currently available therapeutic benefits in type 2 diabetes emphasized blood pressure reduction, lowering of elevated low-density lipoprotein cholesterol, and maintaining optimum blood sugar levels.4 However, along with their recommendation that aspirin therapy should be used "in diabetic persons with any evidence of cardiovascular disease unless absolutely contradicted," the authors should have provided more details, since this is an important therapeutic initiative.
Kajubi SK. Aspirin in the Treatment of Type 2 Diabetes. Arch Intern Med. 2000;160(3):393-394. doi: